CCR8 and colon carcinoma: Anti-CCR8 monoclonal antibody (mAb) treatment of mice inoculated with CT26 colon carcinoma cells significantly reduced Tregs in tumors and enhanced intratumoral IFNγ expression (Villarreal et al. 2018).